RHYTHM Biosciences Ltd Asset Resilience Ratio

Latest as of December 2025: 2.74%

RHYTHM Biosciences Ltd asset resilience ratio. RHYTHM Biosciences Ltd (RHY) has an Asset Resilience Ratio of 2.74% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read RHYTHM Biosciences Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

AU$85.00K
≈ $60.14K USD Cash + Short-term Investments

Total Assets

AU$3.10 Million
≈ $2.19 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of RHYTHM Biosciences Ltd (2018–2025)

Asset resilience ratio of RHYTHM Biosciences Ltd from 2018 to 2025. This chart shows how RHYTHM Biosciences Ltd's Asset Resilience Ratio has changed over time. See RHY cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.

Liquid Assets Composition Over Time

This chart breaks down RHYTHM Biosciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see RHYTHM Biosciences Ltd (RHY) total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$85.00K 2.74%
Total Liquid Assets AU$85.00K 2.74%

Asset Resilience Insights

  • Limited Liquidity: RHYTHM Biosciences Ltd maintains only 2.74% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

RHYTHM Biosciences Ltd Industry Peers by Asset Resilience Ratio

Compare RHYTHM Biosciences Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Voxel S.A.
WAR:VOX
Diagnostics & Research 0.32%
Leveljump Healthcare Corp
V:JUMP
Diagnostics & Research 32.45%
Prodia Widyahusada Tbk PT
JK:PRDA
Diagnostics & Research 7.82%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%

RHYTHM Biosciences Ltd Asset Resilience Ratio by Year (2018–2025)

RHYTHM Biosciences Ltd asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for RHYTHM Biosciences Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 3.00% AU$85.00K
≈ $60.14K
AU$2.83 Million
≈ $2.00 Million
+0.04pp
2024-06-30 2.96% AU$45.00K
≈ $31.84K
AU$1.52 Million
≈ $1.07 Million
+2.38pp
2023-06-30 0.58% AU$45.00K
≈ $31.84K
AU$7.70 Million
≈ $5.45 Million
+0.05pp
2022-06-30 0.53% AU$45.00K
≈ $31.84K
AU$8.44 Million
≈ $5.97 Million
-73.52pp
2021-06-30 74.06% AU$2.27 Million
≈ $1.61 Million
AU$3.07 Million
≈ $2.17 Million
+4.40pp
2020-06-30 69.65% AU$1.84 Million
≈ $1.30 Million
AU$2.65 Million
≈ $1.87 Million
-6.97pp
2019-06-30 76.63% AU$4.77 Million
≈ $3.38 Million
AU$6.23 Million
≈ $4.41 Million
-16.00pp
2018-06-30 92.62% AU$7.83 Million
≈ $5.54 Million
AU$8.45 Million
≈ $5.98 Million
--
pp = percentage points

About RHYTHM Biosciences Ltd

AU:RHY Australia Diagnostics & Research
Market Cap
$14.62 Million
AU$20.66 Million AUD
Market Cap Rank
#25937 Global
#1135 in Australia
Share Price
AU$0.06
Change (1 day)
+0.00%
52-Week Range
AU$0.06 - AU$0.26
All Time High
AU$2.00
About

Rhythm Biosciences Limited, a medical diagnostics company, provides blood tests for the detection of cancers in Australia and the United States. It offers ColoSTAT, a blood test for the early detection of colorectal cancer; and geneType, a personalized predictive test for predicting risk of chronic disease development. The company was incorporated in 2017 and is headquartered in Parkville, Austra… Read more